Among them, Mindray Medical's 2024 third quarter report shows that in the first three quarters of this year, the company achieved a revenue of 29.48 billion yuan, a year-on-year increase of 8.0%; The net profit attributable to the parent company was 10.64 billion yuan, a year-on-year increase of 8.2%, with a growth rate of 11% after excluding the impact of foreign exchange gains and losses; The net operating cash flow reached 11.07 billion yuan, a year-on-year increase of 42.5%.

 

 

 

According to the 2024 third quarter performance report disclosed by Lianying Medical, the company achieved a revenue of 6.954 billion yuan in the first three quarters, a year-on-year decrease of 6.43%; The net profit attributable to shareholders of the listed company was 671 million yuan, a year-on-year decrease of 36.94%. The total R&D investment was 1.635 billion yuan, a year-on-year increase of 14.32%.

 

 

 

Haochen Medical disclosed its third quarter report for 2024. In the first three quarters, the company achieved a revenue of 635 million yuan, a year-on-year increase of 21.27%; The net profit attributable to the parent company was 13.4967 million yuan, a year-on-year decrease of 17.31%; Deducting non net profit of 12.9915 million yuan, a year-on-year decrease of 8.63%; The net cash flow generated from operating activities was 43.0663 million yuan, a year-on-year decrease of 5.89%; During the reporting period, Haochen Medical's basic earnings per share were 0.0161 yuan, with a weighted average return on equity of 3.07%.

 

 

 

Yuyue Medical has released its third quarter report for 2024. According to the announcement, Yuyue Medical achieved a revenue of 6.028 billion yuan, a net profit attributable to the parent company of 1.532 billion yuan, and a net profit after deducting non recurring expenses of 1.274 billion yuan in the first three quarters.

 

 

 

In the third quarter of 2024, Sili Medical reported that the company achieved a revenue of 316 million yuan, a year-on-year increase of 1.57%; Net profit was 65.5785 million yuan, a year-on-year increase of 8.17%, with a sales gross profit margin of 48.77%.

 

 

 

Jiu'an Medical disclosed its third quarter report for 2024. In the first three quarters, the company achieved a revenue of 2.092 billion yuan, a year-on-year decrease of 23.79%; The net profit attributable to the parent company was 1.369 billion yuan, a year-on-year increase of 52.63%; Deducting non recurring net profit of 1.377 billion yuan, a year-on-year increase of 100.83%.

 

 

 

 

Some securities firms believe that the policy of exchanging old for new products is expected to gradually be implemented in various provinces in December of this year and Q1 of 2025. Relevant internal bidding has been launched, and equipment manufacturers are expected to have a large number of orders for exchanging old for new products in the fourth quarter. In addition, considering the relatively low overall performance base of the medical equipment sector in the second half of 2023, the medical equipment sector is expected to enter a high growth range of performance.

 

 

 

The research report of Fangzheng Securities also pointed out that the trend of recovery in the medical imaging equipment sector is evident, and the demand for equipment procurement is expected to be released in the fourth quarter. In 2024, the medical imaging sector experienced a slowdown in performance growth due to the first year of implementation of the healthcare industry rectification and equipment renewal policies, as well as delays in the pace of bidding and procurement within hospitals in various regions. Entering the fourth quarter, the national equipment renewal bidding has significantly accelerated, and the bidding amount for various medical equipment has rapidly increased. Medical imaging equipment is the main bidding category, especially for mid to high end equipment such as 128 row and above CT and 3T magnetic resonance imaging. Domestic imaging leading enterprises are expected to benefit from the release of procurement demand and achieve a significant rebound in performance in the fourth quarter with a rich and high-end product matrix.

 

 

 

At the same time, the bank believes that AI is driving the expansion of the medical imaging application market, and leading enterprises are accelerating their intelligent layout. Artificial intelligence technology is deeply empowering medical imaging, bringing significant improvements to the efficiency and accuracy of medical services from multiple aspects such as auxiliary diagnosis, quality control, surgical planning, and precision treatment. The market for large-scale medical imaging equipment empowered by AI has also achieved rapid growth in recent years, demonstrating great potential for development. In the short term, with the accelerated implementation of equipment renewal policies in various regions, the demand for bidding and procurement within the hospital is expected to enter an accelerated release stage, and domestic imaging equipment enterprises are expected to benefit significantly, achieving a bottoming out and rebound in performance; In the long run, the demand for high-end and intelligent products is growing rapidly, and the potential of AI empowering the medical imaging market is enormous. Domestic leaders are accelerating their layout and preparing for long-term growth drivers. It is recommended to pay attention to companies such as Lianying Medical, Mindray Medical, and Aohua Endoscopy.